# GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

> **NCT00074022** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Recurrent Prostate Cancer
- Stage III Prostate Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
- Stage IV Prostate Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** GTI-2040
- **DRUG:** docetaxel
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00074022
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074022, "GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00074022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*